Patents Assigned to Pulmagen Therapeutics (Inflammation) Limited
  • Respiratory disease treatment
    Patent number: 9078885
    Abstract: A pharmaceutical composition adapted for pulmonary administration by inhalation is described, wherein the composition comprises a glitazone and one or more pharmaceutically acceptable carriers and/or excipients, wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer, and wherein the glitazone is pioglitazone or rosiglitazone or a pharmaceutically acceptable salt thereof, and wherein the glitazone is in the form of microparticles.
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: July 14, 2015
    Assignee: Pulmagen Therapeutics (Inflammation) Limited
    Inventors: Harry Finch, Craig Fox, Mohammed Sajad, Monique Bondil Van Niel, Andrew Forrest
  • Respiratory Disease Treatment
    Publication number: 20140248357
    Abstract: A pharmaceutical composition adapted for pulmonary administration by inhalation is described, wherein the composition comprises a glitazone and one or more pharmaceutically acceptable carriers and/or excipients, wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer, and wherein the glitazone is pioglitazone or rosiglitazone or a pharmaceutically acceptable salt thereof, and wherein the glitazone is in the form of microparticles.
    Type: Application
    Filed: April 7, 2014
    Publication date: September 4, 2014
    Applicant: PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED
    Inventors: Harry Finch, Craig Fox, Mohammed Sajad, Monique Bondil Van Niel, Andrew Forrest
  • Respiratory disease treatment
    Patent number: 8815837
    Abstract: There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation, which composition comprises a glitazone, such as pioglitazone or rosiglitazone, and one or more pharmaceutically acceptable carriers and/or excipients, and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and kit.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: August 26, 2014
    Assignee: Pulmagen Therapeutics (Inflammation) Limited
    Inventors: Harry Finch, Craig Fox, Mohammed Sajad, Monique Bondil Van Niel, Andrew Forrest
  • Respiratory Disease Treatment
    Publication number: 20120264787
    Abstract: There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation, which composition comprises a glitazone, such as pioglitazone or rosiglitazone, and one or more pharmaceutically acceptable carriers and/or excipients, and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and kit.
    Type: Application
    Filed: June 29, 2012
    Publication date: October 18, 2012
    Applicant: Pulmagen Therapeutics (Inflammation) Limited
    Inventors: Harry FINCH, Craig FOX, Mohammed SAJAD, Monique Bodil VAN NIEL, Andrew FORREST
  • Respiratory disease treatment
    Patent number: 8236786
    Abstract: There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation, which composition comprises a glitazone, such as pioglitazone or rosiglitazone, and one or more pharmaceutically acceptable carriers and/or excipients, and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and kit.
    Type: Grant
    Filed: August 4, 2010
    Date of Patent: August 7, 2012
    Assignee: Pulmagen Therapeutics (Inflammation) Limited
    Inventors: Harry Finch, Craig Fox, Mohammed Sajad, Monique Bodil Van Niel, Andrew Forrest
  • Tetrahydropyrrolopyrimidinediones and their use in therapy
    Patent number: 8198288
    Abstract: The subject invention provides compounds of formula (1): including monomers and multimers thereof that are inhibitors of human neutrophil elastase (HNE) activity and are useful in the treatment of diseases or conditions in which HNE plays a part.
    Type: Grant
    Filed: November 4, 2008
    Date of Patent: June 12, 2012
    Assignee: Pulmagen Therapeutics (Inflammation) Limited
    Inventors: Nicholas Charles Ray, Harry Finch, Christine Edwards, Elizabeth O'Connor
  • Sulfonamide Compounds for the Treatment of Respiratory Disorders
    Publication number: 20120041043
    Abstract: Compounds of formula (I) are agonists of PPAR?, useful for the treatment of respiratory disease; formula (I): wherein R1, R2 or R3 each independently represents halo, cyano, nitro, amino, alkyl, haloalkyl, alkoxy, haloalkoxy, carboxylic acid or an ester or amide thereof; R4 represents hydrogen or alkyl; m, n or p independently represents 0, 1, 2 or 3.
    Type: Application
    Filed: December 23, 2009
    Publication date: February 16, 2012
    Applicants: Pulmagen Therapeutics (Inflammation) Limited, Dr. Reddy's Laboratories LTD
    Inventors: Vidya Ramdas, Harry Finch, Craig Fox